Oct. 17, 2024 — Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the immunotherapy nivolumab to a current treatment regimen.
Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...
Hodgkin lymphoma (formerly known as Hodgkin disease), which involves an abnormal type of lymphocyte called Reed-Sternberg cells Non-Hodgkin lymphoma, which does not contain Reed-Sternberg cells ...
About 7% of all cancers in children and teens are non-Hodgkin lymphomas (NHLs). About 1,200 children and teens are diagnosed with NHL in the United States each year. NHL is about 2 to 3 times more ...
Scientists are unraveling the mystery of what triggers Huntington’s disease, a devastating and fatal hereditary disorder that strikes in the prime of life, causing nerve cells in parts of the ...
Scientists are unraveling the mystery of what triggers Huntington’s disease, a devastating hereditary disorder that strikes in the prime of life Scientists are unraveling the mystery of what ...
T-cell skin lymphomas are more common than B-cell skin lymphomas. T-Cell Skin Lymphoma Cutaneous T-cell lymphoma (CTCL) occurs when a mutation causes the cell to divide too quickly and stay alive too ...